Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,513 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.
Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Foss FM, Jain S. Stuver RN, et al. Among authors: jain s. Am J Hematol. 2019 Jun;94(6):641-649. doi: 10.1002/ajh.25463. Epub 2019 Apr 9. Am J Hematol. 2019. PMID: 30896890 Free PMC article. Clinical Trial.
Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas.
Koh MJ, Merrill MH, Koh MJ, Stuver R, Alonso CD, Foss FM, Mayor AM, Gill J, Epeldegui M, Cachay E, Thorne JE, Silverberg MJ, Horberg MA, Althoff KN, Nijhawan AE, McGinnis KA, Lee JS, Rabkin CS, Napravnik S, Li J, Castilho JL, Shen C, Jain S. Koh MJ, et al. Among authors: jain s. Blood Adv. 2022 Mar 8;6(5):1420-1431. doi: 10.1182/bloodadvances.2021006208. Blood Adv. 2022. PMID: 35026839 Free PMC article.
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
Ryu Tiger YK, Jain S, Barta SK, Tolu S, Estrella B, Sawas A, Lue JK, Francescone MM, Pro B, Amengual JE. Ryu Tiger YK, et al. Among authors: jain s. Leuk Lymphoma. 2024 Jun;65(6):736-745. doi: 10.1080/10428194.2024.2329996. Epub 2024 Mar 22. Leuk Lymphoma. 2024. PMID: 38517235 Clinical Trial.
Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.
Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O'Connor OA. Jain S, et al. Clin Cancer Res. 2015 May 1;21(9):2096-106. doi: 10.1158/1078-0432.CCR-14-2249. Epub 2015 Feb 12. Clin Cancer Res. 2015. PMID: 25677697
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Nahas MR, Soiffer RJ, Kim HT, Alyea EP 3rd, Arnason J, Joyce R, Antin JH, Ho VT, Stroopinsky D, Li S, Levine JD, McMasters M, Jain S, Hamdan A, Tzachanis D, Bryant MP, Logan EK, Bazemore J, Stewart J, Joyce A, Stephenson S, Washington A, Cole L, Pyzer A, Leaf RK, Avigan DE, Rosenblatt J. Nahas MR, et al. Among authors: jain s. Blood. 2018 Jun 21;131(25):2836-2845. doi: 10.1182/blood-2017-05-780239. Epub 2018 Mar 16. Blood. 2018. PMID: 29549175 Free article. Clinical Trial.
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.
Wu G, Yoshida N, Liu J, Zhang X, Xiong Y, Heavican-Foral TB, Mandato E, Liu H, Nelson GM, Yang L, Chen R, Donovan KA, Jones MK, Roshal M, Zhang Y, Xu R, Nirmal AJ, Jain S, Leahy C, Jones KL, Stevenson KE, Galasso N, Ganesan N, Chang T, Wu WC, Louissaint A, Debaize L, Yoon H, Dal Cin P, Chan WC, Ho Sui SJ, Ng SY, Feldman AL, Horwitz SM, Adelman K, Fischer ES, Chen CW, Weinstock DM, Brown M. Wu G, et al. Among authors: jain s. Sci Transl Med. 2023 Sep 20;15(714):eadi7244. doi: 10.1126/scitranslmed.adi7244. Epub 2023 Sep 20. Sci Transl Med. 2023. PMID: 37729434 Free PMC article.
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S, Stroopinsky D, Yin L, Rosenblatt J, Alam M, Bhargava P, Clark RA, Kupper TS, Palmer K, Coll MD, Rajabi H, Pyzer A, Bar-Natan M, Luptakova K, Arnason J, Joyce R, Kufe D, Avigan D. Jain S, et al. Blood. 2015 Jul 16;126(3):354-62. doi: 10.1182/blood-2015-02-628149. Epub 2015 Jun 5. Blood. 2015. PMID: 26048911 Free PMC article.
10,513 results
You have reached the last available page of results. Please see the User Guide for more information.